Timolol Maleate is a non-selective beta-adrenergic receptor blocker that effectively reduces elevated intraocular pressure, regardless of glaucoma presence. Its onset of action begins around 20 minutes after ocular administration, with peak effectiveness within 1 to 2 hours. The pressure-lowering effect may last up to 24 hours with concentrations of 0.25% or 0.50%. Unlike miotics, Timolol typically does not affect pupil size or visual acuity.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Timo-Comod 0.5% eye Drops is indicated for reducing intraocular pressure in patients with:
Ocular:
Mild irritation (e.g., conjunctivitis, keratitis, blepharitis)
Visual disturbances, including refractive changes (especially after stopping miotics)
Cardiovascular:
Bradycardia, arrhythmias, hypotension, heart block, syncope, cardiac arrest
Respiratory:
Dyspnea, bronchospasm, respiratory failure (especially in asthmatic patients)
Systemic:
Headache, nausea, dizziness, fatigue, depression
Initial dose: One drop of 0.25% solution, instilled into the affected eye twice daily.
If intraocular pressure is not adequately controlled, increase to a 0.50% solution, one drop twice daily.
Once pressure stabilizes, dosage may be reduced to once daily based on clinical evaluation after about 4 weeks.
Pediatric use: Not recommended in premature infants or newborns due to a lack of clinical studies.
Systemic beta-blockers may amplify the hypotensive and bradycardic effects.
Caution when used with adrenaline-containing eye drops, as pupil dilation (mydriasis) may occur.
Clinical supervision is advised with concomitant therapies that may depress cardiac or respiratory function.
Known hypersensitivity to Timolol or formulation components
Patients with:
Timolol may be absorbed systemically and can exert systemic beta-blocker effects. Caution is advised in elderly and cardiac-compromised patients.
Use is generally well tolerated, but wearing contact lenses during treatment is discouraged due to:
Reduced tear secretion from beta-blockers
Possible drug absorption onto lenses
Safety in human pregnancy has not been adequately established.
Use only if the potential benefit justifies the potential risk to the fetus or nursing infant.
Monitor closely in patients with:
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.